

1255223

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

December 01, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

**APPLICATION NUMBER: 60/512,212
FILING DATE: *October 17, 2003*
RELATED PCT APPLICATION NUMBER: *PCT/US04/34448***

Certified by



Jon W Dudas

Acting Under Secretary of Commerce
for Intellectual Property
and Acting Director of the U.S.
Patent and Trademark Office



PROVISIONAL PATENT APPLICATION COVER SHEET

This is a request for filing a PROVISIONAL PATENT APPLICATION under 37 C.F.R. §1.53(c).

16711 U.S. PTO
10/17/03

Docket
Number

05627.0010.PZUS00

INVENTOR(S)/APPLICANT(S):

LAST NAME	FIRST NAME	MIDDLE INITIAL	RESIDENCE (CITY AND EITHER STATE OR FOREIGN COUNTRY)
I. Zang	Ying	C. Q.	Missouri City, TX

TITLE OF THE INVENTION

A Method for Increasing CD8⁺ Cytotoxic T Cell Responses and For Treating Multiple Sclerosis

CORRESPONDENCE ADDRESS

Attention: IP Prosecution
HOWREY SIMON ARNOLD & WHITE, LLP
Box 34, 1299 Pennsylvania Avenue, N.W.
Washington, D.C. 20004-2402

STATE	DC	ZIP CODE	20004-2402	COUNTRY	USA
-------	----	----------	------------	---------	-----

ENCLOSED APPLICATION PARTS (check all that apply)

☒ Specification /Claims/Abstract Number of Pages: 26 ☒ Sequence Listing Number of Pages: 2

☒ Drawing(s) Number of Sheets: 8

METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL PATENT APPLICATION (check one)

A check or money order is enclosed to cover the Provisional Patent Application filing fees	Pro- visional Filing Fee Amount(s)	\$ 160.00
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any deficiencies in filing fees, or credit overpayments, to Deposit Account Number: 08-3038		(less one-half if small entity) = \$80.00

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

☒ No.

☐ Yes, the name of the U.S. Government agency and the Government contract number are:

Respectfully submitted,

SIGNATURE

Date October 17, 2003

TYPED or PRINTED NAME David W. Clough, Ph.D.

REGISTRATION NO. 36,107
(if appropriate)

PROVISIONAL PATENT APPLICATION FILING ONLY

PROVISIONAL APPLICATION TRANSMITTAL
(37 C.F.R. §1.53(c))

Attorney Docket No. 05627.0010.PZUS00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Mail Stop Provisional Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing under 37C.F.R.
§1.53(c) is the provisional patent application
of:

Ying C. Q. Zang

Title: A Method for Increasing CD8⁺ Cytotoxic
T Cell Responses and for Treating
Multiple Sclerosis

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"Express Mail" Mailing Label Number


EV 023935085 US

Date of Deposit October 17, 2003

I hereby certify that this paper or fee is being deposited with
the United States Postal Service "Express Mail Post Office to
Addressee" Service under 37 CFR §1.10 on the date
indicated above and is addressed to Mail Stop Provisional
Patent Application, Commissioner for Patents, P.O. Box
1450, Alexandria, VA 22313-1450

Nate Le

(Typed or printed name of person mailing)


(Signature of person mailing)

PROVISIONAL PATENT APPLICATION TRANSMITTAL

Enclosed are:

1. (x) Cover Sheet for the above-identified provisional patent application identifying the application as a provisional application.

2. Application Papers Enclosed

# of Specification pages:	<u>23</u>	
# of Claims:	<u>2</u>	
# of Abstract pages:	<u>1</u>	
# of Sheets of Drawings:	<u>8</u>	() Formal (x) Informal
# of Sequence Listing pages:	<u>2</u>	

3. Provisional Application Filing Fee

- () A check in the amount of \$ 160.00 to cover the filing fee for the above-identified provisional patent application **without** a claim of small entity status.
- () A check in the amount of \$ 80.00 to cover the filing fee for the above-identified provisional patent application by an entity claiming small entity status.

PROVISIONAL PATENT APPLICATION
Attorney Docket No. 05627.0010.PZUS00

4. Method of Payment of Fees

() Enclosed is our firm check in the amount of: \$ _____

(X) Charge \$ 80.00 Deposit Account No. 08-3038.

5. () A separate written request under 37 C.F.R. §1.136(a)(3) which is a general authorization to treat any concurrent or future reply requiring a petition for an extension of time under 37 C.F.R. §1.136(a) for its timely submission as incorporating a petition for an extension of time for the appropriate length of time therein.


6. (x) The Commissioner is hereby authorized to charge any additional fees which may be required in this application under 37 C.F.R. §§1.16-1.17 during its entire pendency, or credit any overpayment, to Deposit Account No. 08-3038. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 08-3038. This sheet is filed in triplicate.

Please direct all future communications to:

HOWREY SIMON ARNOLD & WHITE, LLP
Attention: IP Prosecution
Box No. 34
1299 Pennsylvania Avenue, N.W.
Washington, D.C. 20004-2402
(202) 783-0800

Respectfully Submitted,

October 17, 2003
(Date)

By: 
David W. Clough, Ph.D.
Registration No. 36,107

HOWREY SIMON ARNOLD & WHITE, LLP
321 N. Clark Street, Suite 3400
Chicago, IL 60610
Direct Line: (312) 595-1408
Fax: (312) 595-2250

A Method for Increasing CD8⁺ Cytotoxic T Cell Responses and for Treating Multiple Sclerosis

Background of the Invention

The United States government may own rights in the present invention pursuant to grant number RO1 NS41289 from the National Institutes of Health.

1. Field of the Invention

The present invention relates generally to the field of treatment of autoimmune disease, such as multiple sclerosis (MS). More particularly, it concerns a CD8⁺ T cell vaccine prepared by using immunogenic fragments of Myelin Basic Protein (MBP).

2. Description of Related Art

Multiple sclerosis (MS) is a demyelinating and chronic inflammatory disease of the central nervous system (CNS). The histopathologic hallmarks of the disease include focal infiltration of both CD4⁺ and CD8⁺ T cells together with other inflammatory cells in the white matter and demyelination with evidence of some axonal damage (Martin *et al.*, Annu. Rev. Immunol. 1992; 10: 53; Keegan *et al.*, Annu. Rev. Med. 2002; 53: 285). It has long been speculated that the T cell responses to certain myelin proteins, such as myelin basic protein (MBP), play an important role in the pathogenesis of MS. In experimental autoimmune encephalomyelitis (EAE), a classic animal model for MS, CD4⁺ T cells recognizing MBP have been found to induce CNS pathology characterized by extensive inflammation and mild demyelination (Zamvil *et al.*, Nature 1985; 317: 355). Until recently it was not known that CD8⁺ T cells recognizing short peptides of MBP can induce EAE with distinct CNS pathology. These CD8⁺ T cells are cytotoxic

toward target cells, recognize endogenously processed MBP and induced severe EAE upon adoptive transfer (Huseby *et al.*, J. Exp. Med. 2001; 194: 669; Steinman, J. Exp. Med., 2001; 194: 27). It is important to note that CNS lesions induced by CD8⁺ cytotoxic T cells recognizing MBP in EAE are characterized by extensive demyelination, closely resembling MS pathology in humans (Huseby *et al.*, *supra*), suggesting that CD8⁺ cytotoxic T cells recognizing MBP are capable of causing injury of oligodendrocytes expressing both MHC class I molecules and MBP. These findings have raised new questions as to whether CD8⁺ cytotoxic MBP-reactive T cells play a similar role in MS.

In MS, there is some evidence indicating that the CD4⁺ T cell responses to MBP and other candidate myelin antigens may play an important role in the disease processes (Ota *et al.*, Nature 1990; 346: 183; Martin *et al.*, J. Exp. Med. 1991; 173: 19; Zhang *et al.*, Ann. Neurol. 1992; 32: 330; Trotter *et al.*, J. Neuroimmunol. 1998; 84: 172; Markovic-Plese *et al.*, J. Immunol. 1995; 155: 982; Kerlero de Rosbo *et al.*, 1997; 27: 3059; Bieganowska *et al.*, J. exp. Med. 1997; 185: 1585; Wallstrom *et al.*, Eur. J. Immunol. 1998; 28: 3329; Lindert *et al.*, Brain 1999; 122: 2089; Zhang *et al.*, J. Exp. Med. 1994; 179: 973; Tejada-Simon *et al.*, Intern. Immunol. 2000; 12: 1641). The results accumulated so far suggest that CD4⁺ MBP-reactive T cells undergo *in vivo* activation and clonal expansion in MS patients compared to healthy controls (Zhang *et al.*, J. Exp. Med. 1994; 179: 973, Allegretta *et al.*, Science 1990; 247: 718; Chou *et al.*, J. Neurosci. Res. 1989; 23: 207; Vandervyver *et al.*, Eur. J. Immunol. 1995; 25: 958; Wucherpfennig *et al.*, J. Immunol. 1994; 152: 5581) and occur at an increased precursor frequency during acute exacerbation (Tejada-Simon *et al.*, Intern. Immunol. 2000; 12: 1641). Compared to CD4⁺ MBP-reactive T cell counterparts, the potential involvement of CD8⁺ cytotoxic

MBP-reactive T cells in the pathogenesis of MS is unknown. Tsuchida and co-workers reported the identification of CD8⁺ cytotoxic T cells in the blood of MS patients as well as in healthy individuals (Tsuchida *et al.*, Proc. Natl. Acad. Sci. USA 1994; 91: 10859). Some of these CD8⁺ T cell lines appeared to recognize endogenously processed myelin peptides, suggesting their potential role in the injury of oligodendrocytes that constitutively express MHC class I molecules (but not class II molecules) and the myelin antigens. A subsequent study confirmed that HLA-A2 restricted CD8⁺ T cell lines recognizing the 110-118 peptide of MBP could mediate lysis of human oligodendrocytes (Jurewicz *et al.*, J. Immunol. 1998; 160: 3056). However, it remains unknown whether CD8⁺ T cells recognizing MBP are sensitized *in vivo* to undergo activation and expansion in MS patients as compared to healthy controls and whether there are additional epitopes associated with other MHC class I molecules.

Summary of the Invention

The present invention is directed to the isolation and CD8⁺ cytotoxic T cells that recognize multiple sclerosis related antigens including but not limited to antigens such as Myelin Basic Protein (MBP), and/or fragments thereof.

In one embodiment, the present invention is directed to fragments of MBP, which bind HLA-A2 and HLA-A24 receptors with high affinity. Among the fragments of MBP encompassed by the present invention as those set out as SEQ ID NOS: 1-4. The fragments may also be homologs having conservative amino acids at one or more position of the fragment but which still bind to the HLA-A2 and HLA-A24 receptors.

In another embodiment, the present invention describes a method for preparing a vaccine useful in the treatment or prevention of MS comprising obtaining a population of peripheral blood mononuclear cells (PBMCs) comprising T cells from a patient to be treated; enriching said population for CD8⁺ T cells preferably by reducing or depleting the number of CD4⁺ cells in the population; and incubating said CD8⁺ T cell enriched population of one or more peptides corresponding to MBP-fragments capable of binding to HLA-A2 and HLA-A24 so as to increase the number of CD8⁺ T cell clones in the population specific for said MBP polypeptides. The population of CD8⁺ T cells specific responsive to the MBP's may be further expanded by, for example, alternately stimulating said clones with the corresponding MBP peptides and a mitogen, for example, in the presence of antigen presenting cells (APCs).

Yet another embodiment of the present invention discloses methods of testing CD8⁺ T cell vaccines for their cytotoxicity against autologous cells primed with MBP-fragments, including but not limited to peptides having an amino acid sequence correspond to SEQ ID NOS: 1, 2, 3 or 4.

In yet another embodiment, the present invention is concerned with a method of treating MS by administering to a patient in need of the treatment with autologous CD8⁺ T cells responsive to the MBP fragments and preferably capable of binding to HLA-A2 and HLA-A24.

In yet another aspect, the present invention provides a method for producing an autologous CD8⁺ T cell vaccine by means of isolating or generating CD 8⁺ T cell clones that have cytotoxic activity against MPB-reactive CD8⁺ T cells of the patient. Under

these methods, an autologous T cell memory clones are selected for their reactivity against MBP-reactive CD8⁺ T cells of the patient.

The invention is also directed to T cell vaccines such as those described in copending U.S. Patent Application Nos. 09/952,532; PCT/US02/28874; 60/402,521; PCT/US03/24548 (all of which are incorporated herein by reference in their entirety), which are further modified by the addition of the CD8⁺ T cells reactive to MS-related antigens peptide produced according to the methods of the present invention.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A and 1B illustrates percentage of CD4⁺ T cells and CD8⁺ T cells before and after T cell depletion. PBMC derived from an MS patient (MS-4) were analyzed for percentage of CD4⁺ T cells and CD8⁺ T cells before (left panel) and after (right panel) magnetic bead-depletion of CD4⁺ T cells. The rate of CD4⁺ T cell depletion was always greater than 98% in all 30 experiments. The average percentage of CD8⁺ T cells in PBMC depleted for CD4⁺ T cells was 72 ±8%.

Figure 2 shows the estimated precursor frequency of CD8⁺ T cells reactive to MBP-derived peptides in patients with MS and normal subjects (NS). The CD8⁺ T cell frequency analysis was performed by the split-well method in which responder PBMC fractions pre-depleted for CD4⁺ T cells were cultured with irradiated autologous PBMC that were not fractionated in the presence of the indicated MBP-derived peptides, respectively. A synthetic peptide corresponding to an immunodominant epitope of tetanus toxoid (residues 830-838) was used as a control. Each open circle represents the

frequency of CD8⁺ T cells in each individual. The data are expressed as the estimated frequency of CD8⁺ T cells recognizing the MBP-derived peptides in CD4-depleted fractions of PBMC.

Figure 3 shows phenotypic expression of CD8⁺ T cells reactive to MBP-derived peptides. CD8⁺ T cell lines (E11, D10, B9 and F12) were analyzed for the phenotypic expression with a panel of monoclonal antibodies to TCR $\alpha\beta$ /TCR $\gamma\delta$, CD4/CD8, CD45RA/CD45RO.

Figure 4 shows analysis of MHC Class I tetramer for binding to cloned CD8⁺ T cell lines by flow cytometry. Two A2-restricted CD8⁺ T cell lines that recognized MBP₁₁₁₋₁₁₉ peptide (E11) and MBP₈₇₋₉₅ peptide (D10) were analyzed by flow cytometry using an HLA-A2- MBP₁₁₁₋₁₁₉ tetramer. The open profiles represent staining of T cells with a PE-conjugated control antibody. The solid profiles indicate staining of T cells with the tetramer in the same representative experiment.

Figure 5 illustrates the cytokine profile of CD8⁺ T cells recognizing MBP-derived peptides. Cytokine production of the resulting CD8⁺ MBP-reactive T cell lines derived from patients with MS (MS, n=25) and from normal subjects (NS, n=14) was measured by ELISA. The T cell lines were challenged with the corresponding peptide, respectively, and the supernatants were tested after 48 hours for concentrations of the indicated cytokines. The bars indicate the mean concentration (pg/ml) \pm SEM. The detection limit of the assays for all cytokines was less than 25 pg/ml.

Figure 6A and 6B shows cytotoxic activity of CD8⁺ T cell lines recognizing MBP-derived peptides against autologous target cells. Four representative CD8⁺ T cell lines reactive to MBP-derived peptides, E11 for MBP₁₁₁₋₁₁₉, D10 for MBP₈₇₋₉₅, B9 for MBP₁₃₄₋₁₄₂ and F12 for MBP₁₄₋₂₂ were examined for cytotoxicity in LDH-release assays. *Panel A.* CD8⁺ T cell lines were tested for cytotoxic activity against autologous target cells pulsed with corresponding peptides at the indicated effector (CD8⁺ T cells) to target (autologous EBV-transformed B cells) ratio. A synthetic 9-mer peptide corresponding to a unrelated TCR CDR3 sequence (STRQGPQET) (SEQ ID NO: 5) was used as a control. *Panel B.* The same CD8⁺ T cell lines were analyzed for cytotoxicity against autologous target cells pulsed with different peptides of MBP. The same autologous target cells pulsed with the irrelevant TCR peptide served as a control peptide. The effector to target ratio was 10.

Figure 7 illustrates MHC restriction of CD8⁺ cytotoxic T cell lines. The selected CD8⁺ cytotoxic T cell lines recognizing MBP-derived peptides were tested for specific cytotoxicity against autologous target cells in the presence and absence of two monoclonal antibodies to MHC class I (W6/32) and class II (HB55) used at a concentration of 20 µg/ml. The effector to target ratio was 10 for all experiments. Data are expressed as % specific cytotoxicity. The procedure used is the same as that described in the Figure 5 legend.

Figure 8 shows cytotoxic activity of CD8⁺ T cell lines reactive to MBP-derived peptides against COS cells transfected with human MBP and HLA-A2 genes.

The selected CD8⁺ cytotoxic T cell lines were tested for cytotoxic activity in LDH-release assays using COS cells transfected with human MBP and HLA-A2 genes. The effector to target ratio was 10. Non-transfected COS cells were used as a control.

DETAILED DESCRIPTION OF THE INVENTION

Autoreactive T cells of CD4 and CD8 subsets recognizing myelin basic protein (MBP) contribute in the pathogenesis of multiple sclerosis (MS). Unlike CD4⁺ MBP-reactive T cells that induce extensive CNS inflammation and mild demyelination in EAE, CD8⁺ cytotoxic T cells recognizing MBP-derived peptides directly contribute to severe CNS demyelination in EAE presumably through induction of injury of oligodendrocytes (Huseby *et al.*, J. Exp. Med. 2001; 194:669). The distinct role of these CD8⁺ cytotoxic T cells is of particular relevance to MS where demyelination represents the most significant CNS pathology associated with neurologic deficits. There is evidence in the literature on the CD4⁺ T cell responses to candidate myelin antigens in MS and the preliminary therapeutic attempts to suppress or eliminate CD4⁺ myelin-reactive T cells (Zhang *et al.*, Science 1993; 261: 1451; Vandenbark *et al.*, Nat. Med. 1996; 10: 1109). In contrast, and, the functional properties and the potential role of CD8⁺ T cells in recognizing myelin antigens in MS are virtually unknown. Part of the reason for lack of advances in this area is related to technical difficulties in detection and generation of CD8⁺ T cells reactive to myelin antigens. This invention discloses an approach for identifying CD8⁺ T cells that are reactive to MS associated antigens, preferably MBP and/or fragments thereof and the effective generation of CD8⁺ T cell lines, which are useful in the treatment of MS in monitoring the progression of the disease and the monitoring of therapeutic response to

treating of the disease. The methods of the present invention are also useful for the diagnosis and monitoring of the progression of MS.

The approach includes obtaining PBMCs from an MS patient in need of treatment; pre-depleting the population of PBMCs of CD4⁺ T cells resulting population of PBMCs enriched for CD8⁺ cells with MS associated antigens so as to increase the number of CD8⁺ T cells in the population and optionally repeating the stimulation cycle in the presence or absence of antigen presenting cells. Methods of selecting CD8⁺ T cell lines with reactivity to particular antigens, including immunogenic fragments of MBP In the context, immunogenic means the ability to induce or sustain a T cell response including but not limited to a proliferative response or the example to stimulate the production of cotoxins by T cells. The methods of identifying MBP immunogenic fragments are also disclosed and amino acid sequences for four MBP immunogenic fragments with high binding affinity to HLA-A2 and HLA-A24 are provided.

The data described herein provides important evidence that CD8⁺ cytotoxic T cells recognizing MBP-derived peptides are involved in the pathogenesis of MS and therefore indicates the need for development of treatments that would reduce the number of these CD8⁺ cytotoxic T cells in MS patients.

The estimated frequency of CD8⁺ cytotoxic T cells recognizing the identified MHC class I peptides of MBP is in the range of 3.4 to 5.4×10^{-7} in PBMC derived from MS patients and $1.1 - 2.0 \times 10^{-7}$ in the control group. There are several issues related to this finding. First, the observed frequency of CD8⁺ cytotoxic T cells recognizing the identified regions of MBP in PBMC is relatively lower than that of CD4⁺ T cells recognizing immunodominant peptides of MBP in MS patients ($1 - 2 \times 10^{-6}$ in PBMC)

under the same experimental condition (Ota *et al.*, Nature 1990; 346: 183; Zhang *et al.*, J. Exp. Med. 1994; 179: 973; Tejada-Simon *et al.*, Inern. Immunol. 2000; 12: 1641). Like CD4⁺ MBP-reactive T cells, these CD8⁺ cytotoxic MBP-reactive T cells can also be detected in healthy individuals (Ota *et al.*, Nature 1990; 346: 183; Martin *et al.*, J. Exp. Med. 173: 19; Zhang *et al.*, J. Exp. Med. 1994; 179: 973; Tejada-Simon *et al.*, Inern. Immunol. 2000; 12: 1641). However, the estimated T cell frequency is significantly higher in MS patients than that in controls. The differences appear to be more significant than those for CD4⁺ MBP-reactive T cells seen in MS patients and controls. It should also be noted that unlike CD4⁺ MBP-reactive T cells that are naïve T cells expressing both CD45RA and CD45RO (Muraro *et al.*, J. Immunol. 2000; 164: 5474), these CD8⁺ cytotoxic T cells identified here belong to antigen-experienced memory T cell subset expressing CD45RO but not CD45RA phenotype. Secondly, the finding suggests that these CD8⁺ cytotoxic T cells recognizing MBP-derived peptides may undergo in vivo activation in MS patients.

In this regard, there is increasing evidence indicating that MBP-reactive T cells can be activated by a variety of microbial antigens through the mechanism known as molecular mimicry (Oldstone, Curr. Topics Microbiol. Immunol. 1989; 145: 127; Oldstone, FASEB J. 1998; 12: 1255; Hafler, J. Clin. Invest. 1999; 104: 527; Tejada-Simon *et al.*, Annals of Neurology 2003; 53: 189). Recently, we identified sequence homology between HHV-6, a suspected etiologic agent for MS, and MBP and demonstrated that CD4⁺ T cells cross-reactive with both antigens are sensitized in MS patients as opposed to healthy individuals (Tejada-Simon *et al.*, Annals of Neurology 2003; 53: 189). Although the regions of MBP identified here do not share complete

sequence homology with myelin proteins, it is established that TCR degeneracy occurs in MBP-reactive T cells, which renders them able to recognize microbial antigenic peptides of incomplete sequence match as long as the TCR contact residues required for T cell recognition are preserved (Wucherpfennig *et al.*, Cell 1995; 80: 695; Hemmer *et al.*, J. Exp. Med. 1997; 185: 1651; Kozovska *et al.*, Eur. J. Immunol. 1998; 28: 1894). Finally, it is arguable that although the cell culture-based split-well method has been proven useful in comparing the T cell frequency between individual samples when used consistently (Ota *et al.*, Nature 1990; 346: 183; Zhang *et al.*, J. Exp. Med. 1994; 179: 973; Tejada-Simon *et al.*, Intern. Immunol. 2000; 12: 1641; Zhang *et al.*, Science 1993; 261: 1451; Tejada-Simon *et al.*, J. Virol. 2002; 76: 6147), the actual precursor frequency of CD8⁺ cytotoxic T cells may be under-estimated using the method. A number of studies on the precursor frequency analysis of CD4⁺ specific T cells have provided some indications. It has been reported that the frequency of CD4⁺ MBP-reactive T cells in MS is in the range of 4×10^{-5} by ELISPOT based on ex vivo secretion of cytokines in response to antigenic stimulation, which is higher than that measured in $1-2 \times 10^{-6}$ by the split-well method employed here. In this study, however, ELISPOT is not applicable to quantitative detection of CD8⁺ T cells because the source of ex vivo secretion of γ -IFN could not be distinguished between CD8⁺ T cells and CD4⁺ T cells, even though they were irradiated. In this study, further characterization has confirmed that these CD8⁺ T cells recognizing MBP-derived peptides are cytotoxic in nature. They recognize and are cytotoxic toward both autologous target cells pulsed with the MBP peptides and endogenously processed MBP in the context of MHC class I molecules as evidenced in a series of experiments involving COS cells doubly transfected with HLA-A2 and human

MBP genes. This finding is of particular importance in view of a potential role of CD8⁺ cytotoxic T cells in the injury of oligodendrocytes that express both class I molecules and MBP. The findings are in agreement with an earlier study by Jurewicz and colleagues who reported the specific cytotoxicity of CD8⁺ MBP₁₁₀₋₁₁₈ reactive T cells toward A2⁺ human oligodendrocytes (Jurewicz *et al.*, J. Immunol. 1998; 160: 3056). The CD8⁺ cytotoxic T cells reactive to MBP-derived peptides as described here are reminiscent of CD8⁺ T cells of similar functional properties in EAE, which are able to induce extensive CNS demyelination potentially through specific recognition and cytotoxic activity toward oligodendrocytes (Huseby *et al.*, J. Exp. Med. 2001; 194: 669).

The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques disclosed by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

EXAMPLES

Example 1: Identification of MBP fragments with high binding affinity to HLA-A2 and HLA-A24 receptors.

TEPITOPE, (Vaccinome website) an application that allows the identification of HLA class I ligand binding epitopes (Schroers *et al.*, Cancer Res. 2002; 62: 2600; Engelhard Annu. Rev. Immunol. 1994; 12: 181; Manici *et al.*, J. Exp. Med. 1999; 189: 871), was used to

screen amino acid sequence of human myelin basic protein (MBP) for fragments capable of binding to HLA-A2 and HLA-A24. Two fragments with the predicted HLA-A2 binding sequences (1% threshold) and two fragments with predicted HLA-A24 binding sequences (1% threshold) were identified. The amino acid sequences of the fragments are as follows:

Amino acid Sequence of the Fragment	Corresponding SEQ ID NO.	Corresponding Amino acids of Human BMP	Identified for its binding to
MBPVVHFFKNIV	SEQ ID NO. 1	87-95	HLA-A2
SLSRFSWGA	SEQ ID NO. 2	111-119	HLA-A2
DYKSAHKGF	SEQ ID NO. 3	134-142	HLA-A24
KYLATASTM	SEQ ID NO. 4	14-22	HLA-A24

Peptides with SEQ ID NOS: 1-4 were then synthesized using the Mayfield method and were purified using HPLC (MD Anderson Cancer Center Peptide Core, Houston, TX). The purity of the peptides was greater than 90%. HLA-A2-MBP₁₁₁₋₁₁₉ tetramer was obtained from Immunomics (San Diego, CA).

Example 2. Precursor frequency analysis of CD8⁺ T cells recognizing MBP-derived peptides in MS patients and healthy controls

Fifteen patients with relapsing-remitting or secondary progressive MS as determined by the Poser (reference) criteria were included in the study. Patients had not been treated with immunosuppressive or immunomodulatory drugs (Azathioprine, Cyclophosphamide, Beta Interferons or Glatiramer Acetate) at least 3 months before entering the study. The protocol was approved by the Institutional Review Board at

Baylor College of Medicine. A group of 15 healthy subjects matched for age and sex with the MS group was included as controls. The clinical characteristic/demographic data and HLA-A2 and -A24 genotypes of MS patients and control subjects are shown in Table 1.

The precursor frequency of T cells recognizing the selected peptides of MBP with SEQ ID NOS: 1–4 was estimated in MS patients and controls using a split-well method (Ota et al., *Nature* 1990; 346: 183; Zhang et al., *J. Exp. Med.* 1994; 179: 973). The initial attempts to detect CD8⁺ T cell responses to the MBP peptides in unfractionated peripheral blood mononuclear cells yielded low frequencies of specific T cell isolates of mixed CD4⁺ and CD8⁺ phenotypes. The approach to detecting CD8⁺ T cells reactive to MBP-derived peptides was improved subsequently by pre-depleting CD4⁺ T cells. The depletion was achieved by using a method described below.

Peripheral blood mononuclear cells (PBMC) were isolated from the peripheral blood of MS patients and healthy individuals by Ficoll separation. CD4⁺ T cells were pre-depleted using magnetic beads coupled with an anti-CD4 antibody (DynaL ASA, Oslo, Norway). Briefly, PBMC were incubated with magnetic beads coated with the antibody at a bead to cell ratio of 10 for 30 min with gentle shaking. Unbound PBMC fractions were collected by magnetic separation. The depletion rate for CD4⁺ T cells was greater than 98% in all cases. The resulting CD4-depleted fractions typically contained 72 ± 8% CD8⁺ T cells as determined by flow cytometric analysis. A representative experiment is shown in Figure 1.

The resulting PBMC fractions were then seeded in 96-well U-bottomed microtiter plates at a density of 50,000 cells/well together with 10⁵ of autologous unfractionated

PBMC that were irradiated to provide “helper” function of CD4⁺ T cells while they themselves were unable to proliferate in response to the antigens. Peptides with SEQ ID NOS: 1–4 were added at a final concentration of 20 µg/ml to cultures. A total of 32 wells were set for each peptide. A synthetic peptide corresponding to an immunodominant peptide of tetanus toxoid (residues 830-838) was included in the precursor frequency analysis as a negative control. Cells were cultured at 37°C in 5% CO₂ atmosphere. After 7 days, all cultures were tested for specific proliferation to the corresponding peptides by tritiated thymidine incorporation. In brief, each well was split into four aliquots (approximately 10⁴ cells per aliquot) and cultured in duplicate with 10⁵ autologous PBMC in the presence and the absence of the corresponding MBP-derived peptides at 20 µg/ml. Cultures were kept for three days and pulsed with [³H]-thymidine (Nycomed Amersham, Arlington Heights, IL) at 1 µCi per well during the last 16 hours of culture. Cells were then harvested using an automated cell harvester and [³H]-thymidine incorporation was measured in a betaplate counter (Wallac, Turku, Finland).

A well/culture was defined as specific for the peptide when the CPM were greater than 1,500 and exceeded the reference CPM (in the absence of the peptide) by at least three times. The frequency of specific CD8⁺ T cells was then estimated by dividing the number of positive wells by the total number of CD4-depleted PBMC seeded in the initial culture.

As shown in Figure 2, the results revealed that the average precursor frequency of CD8⁺ T cells recognizing MBP-derived peptides was estimated in the range of 3.4 to 5.4X10⁻⁷ in CD4⁺ T cell-depleted PBMC obtained from patients with MS, which was

considerably higher than that in control subjects (1.1 to 2.1×10^{-7}), especially for MBP₁₁₁₋₁₁₉ and MBP₈₇₋₉₅ ($p < 0.05$). In contrast, the frequency of CD8⁺ T cells recognizing an immunodominant epitope (residues 830-838) of tetanus toxoid, a recall antigen, did not differ significantly between MS patients and healthy controls (Figure 2).

Example 3. Phenotypic analysis of generated CD8⁺ T cell lines

A panel of 39 CD8⁺ T cell lines generated in the Example 2 was characterized for phenotypic expression, cytokine profile and specific cytotoxic activity toward autologous target cells. The panel included 25 T cell lines from MS patients and 14 T cell lines from healthy controls and was representative for reactivity to all four MBP-derived peptides (Table 2).

To analyze the phenotypic expression, 10^5 cells of each T cell line were washed in PBS containing 1% FBS and 0.1% sodium azide (FBS-PBS) and re-suspended in 100 μ l FBS-PBS containing a 1:100 dilution of fluorochrome-labeled antibody (Simultest CD4/CD8, CD45RA/CD45RO, TCR α / β /TCR γ / δ , Becton Dickinson Immunocytometry Systems, San Jose, CA) or appropriate Ig isotype controls (γ 2a-FITC/ γ 1-PE, Becton Dickinson Immunocytometry Systems). After incubation for 30 min on ice, the cells were washed three times in FBS-PBS, and fixed in 1% formaldehyde for flow cytometric analysis.

It was found that the selected CD8⁺ T cell lines express TCR α / β /CD8 (>95% on average) but not CD4 (<5%) and CD45RO but not CD45RA, regardless of their reactivity to the various MBP-derived peptides. The findings indicate that the selected T cell lines belong to the CD8⁺ memory T cell subset.

Four out of 39 CD8⁺ T cell lines were successfully cloned from three MS patients and were examined in detail. Two such cloned CD8⁺ T cell lines recognized MBP₁₁₁₋₁₁₉ peptide (E11) (SEQ ID NO: 2) and MBP₈₇₋₉₅ peptide (D10) (SEQ ID NO: 1), respectively, in the context of HLA-A2 while two other CD8⁺ T cell lines were A24 restricted and reacted with MBP₁₃₄₋₁₄₂ peptide (B9) (SEQ ID NO: 3) and MBP₁₄₋₂₂ peptide (F12) (SEQ ID NO: 4). Figure 3 illustrates the representative phenotypic expression of four cloned T cell lines described above. Specific binding of an HLA-A2 tetramer to selected CD8⁺ T cell lines was then examined. Only one tetramer (HLA-A2/MBP₁₁₁₋₁₁₉) could be made successfully by a commercial source. As shown in Figure 4, the HLA-A2/MBP₁₁₁₋₁₁₉ tetramer exhibited greater than 90% specific binding to a CD8⁺ T cell line (E11) recognizing peptide MBP₁₁₁₋₁₁₉ but not to an A2⁺ CD8⁺ T cell line (D10) recognizing peptide MBP₈₇₋₉₅.

Example 4. Cytokine production of CD8⁺ T cell lines

The cytokine profile of the resulting CD8⁺ T cell lines was analyzed to determine whether they belonged to a Th1 or a Th2 subset. The selected T cell lines (n=39) were first challenged with autologous APC pulsed with the corresponding MBP peptides. The cytokine profile was determined quantitatively using ELISA kits (PharMingen, San Diego, CA). Microtiter plates (96-wells, NUNC Maxisorp) were coated overnight at 4⁰C with 1 µg/well of a purified mouse capturing monoclonal antibody to human cytokine (IL-4, IL-10, TNF-α, γ-IFN) (PharMingen). Plates were washed and non-specific binding sites were saturated with 10 % (w/v) fetal bovine serum (FBS) for 1 hour and subsequently washed. Supernatants and cytokine standards were diluted with PBS and

added in duplicate wells. Plates were incubated at 37°C for 2 hr and subsequently washed with PBS-T. Matched biotinylated detecting antibody was added to each well and incubated at room temperature for 2 hours. After washing, avidin-conjugated horseradish peroxidase was added and plates were incubated for 1 hour. 3,3',5,5'-tetramethylbenzidine (TMB, Sigma) was used as a substrate for color development. Optical density was measured at 450 nm using an ELISA reader (Bio-Rad Laboratories, Hercules, CA) and cytokine concentrations were quantitated by Microplate computer software (Bio-Rad) using a double eight-point standard curve.

As seen in Figure 5, the selected CD8⁺ T cell lines recognizing the MBP-derived peptides predominantly produced TNF- α and IFN- γ but not IL-4 and IL-10, thus belonging to a Th1 phenotype. No significant quantitative differences between the MS-derived T cell lines and the T cell lines derived from the control subjects could be discerned.

Example 6. Establishing clones from the representative T cell lines

Four representative T cell lines (E11, D10, B9 and F12) were selected for their recognition of the four MBP peptides and further cloned by limiting dilution. Briefly, T cells were plated out at one cell per well in 96-well U-bottomed plates under limiting dilution conditions in the presence of irradiated PBMC (100,000 cells per well) and phytohemagglutinin-protein (PHA-P) at 2 μ g/ml. Cells were cultured in IL-2 containing medium for 10-12 days with medium change every 3 to 4 days. Growth positive wells were confirmed for the phenotypic expression of CD8 and for reactivity to the corresponding peptides.

The obtained T cell clones were further expanded by alternate stimulation with the corresponding MBP peptides and PHA-P in the presence of autologous APC.

Example 7. Cytotoxicity of MBP-reactive CD8⁺ T cell clones against autologous cells

All 39 selected CD8⁺ T cell lines were analyzed for cytotoxic activity toward autologous target cells. For this purpose, a panel of autologous B cell lines was generated from patients and controls using EBV transformation on a procedure described previously (Zhang *et al.*, J. Neuroimmunol. 1989; 23: 249; Tejada-Simon *et al.*, Immunology 2002; 107:403). The generated cell lines were pulsed with corresponding peptides of BMP and used as autologous target cells. Pulsing of B cells was carried out by incubating cells with MBP-derived peptides or a control T cell receptor peptide (40 µg/ml), respectively, for 2 hrs followed by washing to remove free peptides.

Cytotoxicity test was performed using a lactate dehydrogenase (LDH)-release assay (Promega Madison, WI). LDH release was measured in an enzymatic assay according to manufacturer's instruction. Briefly, CD8⁺ T cells (50,000 effector cells/well) were incubated with autologous cells at an effector to target ratio of 10 and centrifuged once at 250 x g. Unpulsed autologous B cells and non-transfectants were used as controls. RPMI1640 without phenol red was used throughout the assay to avoid the background absorbance. After incubation at 37°C and 5% CO₂ for 4 hr, the plates were centrifuged again. 50 µl of supernatant was transferred to another plate and mixed with Substrate Mix provided in the test kits. The reaction was stopped after 30 min and read at 490 nm absorbance. Specific cytotoxicity was calculated as: %cytotoxicity = (experimental release – spontaneous release) / (maximum release – spontaneous release) x 100.

The results revealed that 21/25 (84%) of MS-derived and 11/15 (73%) control-derived CD8⁺ T cell lines exhibited a specific cytotoxic effect, as defined by specific cytolysis greater than 30%, on autologous target cells pulsed with the corresponding peptide but not on the same autologous target cells that were either unpulsed or pulsed with an irrelevant peptide. However, no significant differences in percentage of specific cytolysis between MS-derived and control CD8⁺ T cell lines could be discerned. Representative experiments with four selected T cell lines derived from three MS patients are shown in Figure 6.

Furthermore, the observed cytotoxic effect was restricted by MHC class I molecules as the cytotoxicity could be inhibited by the addition of a monoclonal antibody (W6/32) to MHC class I molecules while an antibody (HB55) to MHC class II molecules had no effect (Figure 7). For these MHC restriction experiments, purified monoclonal antibodies to MHC class I (W6/32) or MHC class II (HB55) were added at (20 µg/ml) during incubation of effector cells with target cells in cytotoxicity assays described above.

Example 8. Cytotoxicity of MBP-reactive CD8⁺ T cell clones against cells expressing processed MBP in combination with MHC class I molecules

It was important to identify whether selected CD8⁺ T cells have cytotoxic effect on oligodendrocytes that express both MHC class I molecules and endogenously processed MBP. To address this question, the following test was developed. Under the test, COS cells were transfected with HLA-A2*01 gene and human MBP gene. Specifically, cDNA encoding human MBP and human HLA-A2 were constructed into

pBud CE4.1 vector that contained two promoters (P_{CMV} promoter and $P_{EF-\alpha 1}$ promoter). The recombinant DNA was transfected into COS-7 cells using LipofectAMINE 2000 (Invitrogen, San Diego, CA). The stable transfectants were selected using selective medium containing Zeocin at 400 $\mu\text{g/ml}$ (Invitrogen, San Diego, CA). Stable expression of MBP and HLA-A2 were evaluated by incubating the cells with conjugated monoclonal antibodies to MBP (Sigma, St. Louise, MO) or HLA-A2 (BD Pharmingen, San Diego, CA) and analyzed subsequently by flow cytometry.

Selected MS-derived CD8^+ T cell lines that were cytotoxic toward peptide-pulsed autologous target cells were analyzed in cytotoxicity experiments using transfected COS cells. The two HLA-A2 $^+$ CD8^+ T cell lines (E11 and D10) displayed specific cytotoxicity toward A2-MBP transfected COS cells but not non-transfectants while the other CD8^+ cytotoxic T cell lines of A24- restriction (B9 and F12) had no cytotoxic effect on transfected COS cells. Results on four representative CD8^+ T cell lines are shown in Figure 8, indicating specific recognition and cytotoxicity towards target cells expressing both human MBP and HLA-A2.

WHAT IS CLAIMED IS:

1. An autologous T cell vaccine for the treatment of multiple sclerosis made by a process comprising:
 - a) obtaining a population of peripheral blood mononuclear cells (PBMC) comprising T cells from a patient to be treated with the vaccine;
 - b) enriching said population for CD8⁺ T cells by depleting said population of CD4⁺ T cells;
 - c) incubating said CD 8⁺ T cell enriched population with Myelin Basic Protein (MBP) peptides so that to establish CD 8⁺ T cell clones specific for said MBP polypeptides optionally in the presence of antigens presenting cells (APCs); and optionally expanding said CD8⁺ T cells in said population by alternatively stimulating said cells with the said MBP peptides and a mitogen in the presence of antigen presenting cells (APCs).
2. The vaccine of claim 1 wherein said MBP peptide is selected from the group consisting of polypeptide with SEQ ID NO: 1, peptide with SEQ ID NO: 2, peptide with SEQ ID NO: 3, peptide with SEQ ID NO: 4 and any portion, modification or functional substitution of any of said four polypeptides.
3. The vaccine of claim 1 wherein said mitogen is selected from the group consisting of phytohemagglutinin, concanavalin A, pokeweed mitogen, and monoclonal antibodies to CD3.

4. A method of treating of multiple sclerosis comprising administering to a patient in need thereof an autologous T cell vaccine prepared by a method according to claim 1, 2, or 3.
5. A synthetic or isolated polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3: SEQ ID NO: 4 and any portion, modification or functional substitution of any of said four polypeptides.
6. A T cell vaccine comprising an enriched population of CD8⁺ T cells reactive to one or more Multiple Sclerosis (MS) related antigens.
7. The T cell vaccine of claim 6 wherein said MS related antigen is selected from the group consisting of the peptides set out in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4, and any portion, modifications or functional substitution of said peptides.
8. A method for treating multiple sclerosis comprising administering to a patient in need thereof an effective amount of T cell vaccine according to claims 8 or 9.

Table 1. Clinical characteristics and HLA-A2 and A-24 genotypes of MS patients and healthy individuals

Subject	Age	Sex	RR/SP	EDSS	Duration (yrs.)	A*0201/A*2402
MS-1	36	F	RR	0	1	+ / +
MS-2	33	F	RR	1.0	7	+ / +
MS-3	55	F	RR	6.5	9	- / -
MS-4	41	F	RR	3.5	8	+ / -
MS-5	46	F	RR	2.0	11	ND
MS-6	47	F	RR	7.5	16	- / -
MS-7	51	F	SP	6.0	14	- / -
MS-8	54	M	RR	2.5	8	+ / -
MS-9	56	M	RR	6.0	24	+ / -
MS-10	46	F	RR	2.0	8	+ / +
MS-11	53	F	RR	3.5	13	+ / -
MS-12	54	M	RR	3.0	19	- / +
MS-13	44	M	RR	3.0	6	+ / +
MS-14	47	F	SP	4.0	9	- / -
MS-15	63	F	SP	6.5	17	- / +
NS-1	46	M	-	-	-	+ / +
NS-2	34	F	-	-	-	- / +
NS-3	42	F	-	-	-	- / +
NS-4	34	F	-	-	-	+ / +
NS-5	21	M	-	-	-	+ / -
NS-6	22	F	-	-	-	+ / -
NS-7	43	F	-	-	-	ND
NS-8	40	F	-	-	-	+ / -
NS-9	26	M	-	-	-	+ / +
NS-10	45	F	-	-	-	+ / +
NS-11	30	F	-	-	-	+ / -
NS-12	46	F	-	-	-	- / -
NS-13	37	M	-	-	-	+ / +
NS-14	35	F	-	-	-	- / -
NS-15	35	F	-	-	-	- / +


RR, relapsing-remitting MS; SP, secondary progressive MS; EDSS, expanded disability scale score. HLA typing was determined by RT-PCR using specific primers for A*0201 and A*2402.


Table 2. Characteristics of selected CD8⁺ T cell lines for further characterization





Total # of T cell lines	Derived from (# of subjects)	Peptide specificity (# of lines)
25	MS patients (12)	Peptide 111-119 (9) Peptide 87-95 (7) Peptide 134-142 (5) Peptide 14-22 (4)
14	Controls (8)	Peptide 111-119 (3) Peptide 87-95 (4) Peptide 134-142 (4) Peptide 14-22 (3)


Abstract


The present invention relates generally to the field of immunology and development of autologous vaccines. More specifically, the present invention is concerned with a method of treating autoimmune disease Multiple Sclerosis (MS) by means of immunizing patients with autologous CD8⁺ cells activated with fragments of Myelin Basic Protein (MBP). The present invention identifies four immunogenic MBP fragments with high binding affinity to HLA-A2 and HLA-A24 receptors and discloses how to use these fragments in preparing anti-MS vaccine.















A.



B.







Sequence Listing.ST25.txt
SEQUENCE LISTING

<110> Opexa

<120> A Method for Increasing CD8+ Cytotoxic T Cell Responses and for Treating Multiple Sclerosis

<130> Opexa, CD8+ patent

<140> Not available yet

<141> 2003-10-30

<160> 5

<170> PatentIn version 3.2

<210> 1

<211> 9

<212> PRT

<213> Synthetic

<400> 1

Val Val His Phe Phe Lys Asn Ile Val
1 5

<210> 2

<211> 9

<212> PRT

<213> Synthetic

<400> 2

Ser Leu Ser Arg Phe Ser Trp Gly Ala
1 5

<210> 3

<211> 9

<212> PRT

<213> Synthetic

<400> 3

Asp Tyr Lys Ser Ala His Lys Gly Phe
1 5

<210> 4

<211> 9

<212> PRT

<213> Synthetic


<400> 4

Lys Tyr Leu Ala Thr Ala Ser Thr Met
1 5

<210> 5

<211> 9

<212> PRT



Sequence Listing.ST25.txt

<213> Synthetic

<400> 5

Ser Thr Arg Gln Gly Pro Gln Glu Thr
1 5

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/034448

International filing date: 18 October 2004 (18.10.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/512,212
Filing date: 17 October 2003 (17.10.2003)

Date of receipt at the International Bureau: 06 December 2004 (06.12.2004)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse